News & Updates

Polymyxin B loading doses, multiple nephrotoxic drug use up risk of AKI

03 Feb 2022

Polymyxin B-associated nephrotoxicity is still a major concern in China, with the use of polymyxin B loading doses and the combined use of multiple nephrotoxic drugs independently adding to an increased risk of acute kidney injury (AKI), a study has found.

Polymyxin B loading doses, multiple nephrotoxic drug use up risk of AKI

03 Feb 2022

Immunomodulator withdrawal not linked to loss of response in IBD

02 Feb 2022

Among inflammatory bowel disease (IBD) patients, the discontinuation of immunomodulator treatment does not contribute to the risk of loss of response although it may lead to an increase in antidrug antibodies, according to a study.

Immunomodulator withdrawal not linked to loss of response in IBD

02 Feb 2022

Tirzepatide regulates metabolites, lipids in T2D

02 Feb 2022

Treatment with tirzepatide leads to a reduction in body weight and improvement in glycaemic control in individuals with type 2 diabetes (T2D), reports a study. In addition, it modulates metabolites associated with T2D risk and metabolic dysregulation that is consistent with improved metabolic health.

Tirzepatide regulates metabolites, lipids in T2D

02 Feb 2022

Effect of interventions on anthropometric outcomes in PCOS varies by drug

02 Feb 2022

In the management of women with polycystic ovary syndrome (PCOS), metformin at various therapeutic doses appears to reduce body weight, body mass index, and waist circumference when compared with placebo, sitagliptin, and acarbose, according to the results of a meta-analysis. On the other hand, pioglitazone and rosiglitazone contribute to an increase in all three outcomes.

Effect of interventions on anthropometric outcomes in PCOS varies by drug

02 Feb 2022

Brolucizumab shows favourable benefit–risk profile in diabetic macular oedema

01 Feb 2022

At a dose of 6 mg, brolucizumab yields substantial visual gains and anatomical improvements in patients with diabetic macular oedema without increasing the risk of serious adverse ocular events when compared with aflibercept, according to data from two phase III trials.

Brolucizumab shows favourable benefit–risk profile in diabetic macular oedema

01 Feb 2022

Plecanatide may be safely administered with antacid

31 Jan 2022 by

Acid suppression therapy appears to exert no meaningful effect on the efficacy or safety of plecanatide when administered concomitantly, according to a study.

Plecanatide may be safely administered with antacid

31 Jan 2022

Secukinumab safe, effective in children with moderate to severe plaque psoriasis

31 Jan 2022

Treatment with either low- or high-dose secukinumab is effective and well tolerated in paediatric patients with moderate to severe plaque psoriasis, a study has shown.

Secukinumab safe, effective in children with moderate to severe plaque psoriasis

31 Jan 2022

Real-world data reflect promising efficacy, safety of ozanimod for UC

30 Jan 2022 by

The first-in-class sphingosine-1-phosphate receptor modulator ozanimod showed promising efficacy and safety in a relatively treatment-refractory cohort of patients with ulcerative colitis (UC), according to the initial results of a prospective, observational cohort study presented at the Crohn’s and Colitis Congress 2022.

Real-world data reflect promising efficacy, safety of ozanimod for UC

30 Jan 2022

4th shot of COVID vaccine: Is it worthwhile?

29 Jan 2022 by

While a fourth dose of the COVID-19 vaccine boosts antibodies to levels that are higher than the third dose, it is not enough to protect against Omicron infections, according to preliminary data from Israel.

4th shot of COVID vaccine: Is it worthwhile?

29 Jan 2022

Olmesartan-amlodipine single-pill + rosuvastatin reduces SBP, LDL-C in concomitant hypertension, dyslipidaemia

29 Jan 2022 by

Treatment with a single-pill combination (SPC) drug, composed of olmesartan and amlodipine, plus a separate dose of rosuvastatin led to significantly reduced systolic blood pressure (SBP) and low-density lipoprotein cholesterol (LDL-C) levels in patients with concomitant hypertension and dyslipidaemia, according to the LEISURE* trial.

Olmesartan-amlodipine single-pill + rosuvastatin reduces SBP, LDL-C in concomitant hypertension, dyslipidaemia

29 Jan 2022

News & Updates

Filter by Specialty:

Specialty:

Polymyxin B loading doses, multiple nephrotoxic drug use up risk of AKI

Polymyxin B loading doses, multiple nephrotoxic drug use up risk of AKI

Immunomodulator withdrawal not linked to loss of response in IBD

Immunomodulator withdrawal not linked to loss of response in IBD

Tirzepatide regulates metabolites, lipids in T2D

Tirzepatide regulates metabolites, lipids in T2D

Effect of interventions on anthropometric outcomes in PCOS varies by drug

Effect of interventions on anthropometric outcomes in PCOS varies by drug

Brolucizumab shows favourable benefit–risk profile in diabetic macular oedema

Brolucizumab shows favourable benefit–risk profile in diabetic macular oedema

Plecanatide may be safely administered with antacid

Plecanatide may be safely administered with antacid

Secukinumab safe, effective in children with moderate to severe plaque psoriasis

Secukinumab safe, effective in children with moderate to severe plaque psoriasis

Real-world data reflect promising efficacy, safety of ozanimod for UC

Real-world data reflect promising efficacy, safety of ozanimod for UC

4th shot of COVID vaccine: Is it worthwhile?

4th shot of COVID vaccine: Is it worthwhile?

Olmesartan-amlodipine single-pill + rosuvastatin reduces SBP, LDL-C in concomitant hypertension, dyslipidaemia

Olmesartan-amlodipine single-pill + rosuvastatin reduces SBP, LDL-C in concomitant hypertension, dyslipidaemia